Scalper1 News
Beleaguered biotech stock Prosensa (RNA) was up 8% in midday trading on the stock market today after the company reported new data on its Duchenne muscular dystrophy candidate late Monday. Earlier, Prosensa stock was up as much as 30%, to 8.80, a six-month high. Prosensa followed up on DMD patients six months after they’d gone through a 24-week round of treatment with its drug drisapersen. Prosensa reported in September that after the initial Scalper1 News
Scalper1 News